All enrolled patients who received a minimum of a single dose of zosuquidar or placebo through induction have been monitored to the incidence of adverse functions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse activities had been associated with the duration of prolonged and significant https://vannevary111lwh4.iyublog.com/profile